---
title: 'Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review'
date: '2024-12-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39666320/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20241213171204&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSIONS AND RELEVANCE: The results of this review suggest that there
  are limited data to suggest that inadvertent transgene insertion is associated with
  SPCs in the post-CAR-T setting. Nonetheless, evidence-based practical solutions
  and scientific strategies for risk mitigation can be implemented. These include
  optimization of T-cell manufacturing, application of safer synthetic immunobiology,
  and implementation of high-fidelity genomic testing, including baseline screening
  for ...'
disable_comments: true
---
CONCLUSIONS AND RELEVANCE: The results of this review suggest that there are limited data to suggest that inadvertent transgene insertion is associated with SPCs in the post-CAR-T setting. Nonetheless, evidence-based practical solutions and scientific strategies for risk mitigation can be implemented. These include optimization of T-cell manufacturing, application of safer synthetic immunobiology, and implementation of high-fidelity genomic testing, including baseline screening for ...